IGM Biosciences Inc Forecast, price target & analysts
IGM Biosciences Inc Target price 2025 - Analyst rating & recommendation
IGM Biosciences Inc Classifications & Recommendation:
IGM Biosciences Inc Price Target
| Target Price | $1.81 |
| Price | $1.30 |
| Potential |
39.42%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target IGM Biosciences Inc 2026 .
The average IGM Biosciences Inc target price is $1.81.
This is
39.42%
register free of charge
$3.00
130.77%
register free of charge
$0.75
42.31%
register free of charge
|
|
| A rating was issued by 4 analysts: 0 Analysts recommend IGM Biosciences Inc to buy, 2 to hold and 2 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the IGM Biosciences Inc stock has an average upside potential 2026 of
39.42%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.68 | 9.01 |
| 25.82% | 236.01% | |
| EBITDA Margin | -6,907.09% | -672.50% |
| 42.35% | 90.26% | |
| Net Margin | -7,211.42% | -1,132.72% |
| 45.33% | 84.29% |
4 Analysts have issued a sales forecast IGM Biosciences Inc 2025 . The average IGM Biosciences Inc sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an IGM Biosciences Inc EBITDA forecast 2025. The average IGM Biosciences Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
2 IGM Biosciences Inc Analysts have issued a net profit forecast 2025. The average IGM Biosciences Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $-193m | 31.21% |
|---|---|---|
| 2025 |
$-102m
47.22%
Unlock
|
|
Net Margin
| 2024 | -7,211.42% | 45.33% |
|---|---|---|
| 2025 |
-1,132.72%
84.29%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.24 | -1.71 |
| 31.21% | 47.22% | |
| P/E | negative | |
| EV/Sales | negative |
2 Analysts have issued a IGM Biosciences Inc forecast for earnings per share. The average IGM Biosciences Inc EPS is
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $-3.24 | 31.21% |
|---|---|---|
| 2025 |
$-1.71
47.22%
Unlock
|
|
P/E ratio
| Current | -0.40 | 79.49% |
|---|---|---|
| 2025 |
-0.76
90.00%
Unlock
|
|
IGM Biosciences Inc...
Current IGM Biosciences Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| BMO Capital |
Locked
➜
Locked
|
Locked | Dec 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
BMO Capital:
Locked
➜
Locked
|
Dec 06 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
